Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Abstract The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Nature Portfolio
2023-10-01
|
| Ráidu: | npj Breast Cancer |
| Liŋkkat: | https://doi.org/10.1038/s41523-023-00592-5 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|